Lo Andrew
CIK 0001679076 Name as filed on the most recent filing
Filed as Lo Andrew (18)
40 transaction lines · from 18 filings · filed 2018-04-04 to 2025-11-19 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER BridgeBio Pharma, Inc. 3 filings
- ISSUER AbCellera Biologics Inc. 1 filings
- ISSUER Urovant Sciences Ltd. 9 filings
- ISSUER Myovant Sciences Ltd. 2 filings
- ISSUER Axovant Sciences Ltd. 3 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
40 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2025-11-18 |
BridgeBio Pharma, Inc. BBIO |
S, Open-market sale | 30,993 disposed | 66.05 | 2,047,056.66 | Form 4, filing 0001470831-25-000357 | |
| 2025-11-18 |
BridgeBio Pharma, Inc. BBIO |
S, Open-market sale | 24,007 disposed | 65.23 | 1,566,012.62 | Form 4, filing 0001470831-25-000357 | |
| 2025-11-17 |
BridgeBio Pharma, Inc. BBIO |
S, Open-market sale | 36,801 disposed | 66.63 | 2,451,914.47 | Form 4, filing 0001470831-25-000357 | |
| 2025-11-17 |
BridgeBio Pharma, Inc. BBIO |
S, Open-market sale | 3,798 disposed | 67.06 | 254,678.69 | Form 4, filing 0001470831-25-000357 | |
| 2025-05-02 |
BridgeBio Pharma, Inc. BBIO |
S, Open-market sale | 100,000 disposed | 38.50 | 3,849,900.00 | Form 4, filing 0000950170-25-064558 | |
| 2021-12-30 |
BridgeBio Pharma, Inc. BBIO |
P, Open-market purchase | 1,500 acquired | 14.30 | 21,450.00 | Form 4, filing 0000899243-22-000188 | |
| 2021-12-29 |
BridgeBio Pharma, Inc. BBIO |
P, Open-market purchase | 6,000 acquired | 12.90 | 77,400.00 | Form 4, filing 0000899243-22-000188 | |
| 2021-12-03 |
AbCellera Biologics Inc. ABCL |
P, Open-market purchase | 86,938 acquired | 14.02 | 1,218,870.76 | Form 4, filing 0001209191-21-068291 | |
| 2019-06-19 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 4,957 acquired | 8.17 | 40,495.22 | Form 4, filing 0001104659-19-036418 | |
| 2019-06-18 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 6,706 acquired | 8.21 | 55,060.95 | Form 4, filing 0001104659-19-036418 | |
| 2019-06-17 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 6,541 acquired | 8.53 | 55,824.82 | Form 4, filing 0001104659-19-036418 | |
| 2019-06-14 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 7,144 acquired | 7.91 | 56,514.04 | Form 4, filing 0001104659-19-035736 | |
| 2019-06-13 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 7,367 acquired | 7.95 | 58,542.60 | Form 4, filing 0001104659-19-035736 | |
| 2019-06-12 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 7,500 acquired | 8.30 | 62,244.00 | Form 4, filing 0001104659-19-035736 | |
| 2019-06-11 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 7,189 acquired | 8.58 | 61,693.84 | Form 4, filing 0000919574-19-004081 | |
| 2019-06-10 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 7,500 acquired | 8.35 | 62,594.25 | Form 4, filing 0000919574-19-004081 | |
| 2019-06-07 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 6,649 acquired | 7.96 | 52,959.28 | Form 4, filing 0000919574-19-004081 | |
| 2019-06-06 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 7,082 acquired | 8.00 | 56,621.30 | Form 4, filing 0000919574-19-003994 | |
| 2019-06-05 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 6,540 acquired | 8.02 | 52,418.10 | Form 4, filing 0000919574-19-003994 | |
| 2019-06-04 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 7,500 acquired | 7.59 | 56,910.75 | Form 4, filing 0000919574-19-003994 | |
| 2019-06-04 |
Myovant Sciences Ltd. MYOV |
P, Open-market purchase | 2,424,242 acquired | 8.25 | 19,999,996.50 | Form 4, filing 0000919574-19-003993 | |
| 2019-06-03 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 5,424 acquired | 7.71 | 41,814.70 | Form 4, filing 0000919574-19-003949 | |
| 2019-05-31 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 5,071 acquired | 7.70 | 39,042.14 | Form 4, filing 0000919574-19-003949 | |
| 2019-05-30 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 6,951 acquired | 7.97 | 55,417.54 | Form 4, filing 0000919574-19-003949 | |
| 2019-05-30 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 300 acquired | 8.91 | 2,671.98 | Form 4, filing 0000919574-19-003949 | |
| 2019-05-29 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 6,882 acquired | 7.55 | 51,983.19 | Form 4, filing 0000919574-19-003880 | |
| 2019-05-28 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 3,807 acquired | 7.68 | 29,244.61 | Form 4, filing 0000919574-19-003880 | |
| 2019-05-24 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 3,796 acquired | 7.70 | 29,233.38 | Form 4, filing 0000919574-19-003880 | |
| 2019-05-23 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 4,802 acquired | 7.76 | 37,252.00 | Form 4, filing 0000919574-19-003830 | |
| 2019-05-22 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 5,033 acquired | 8.06 | 40,557.93 | Form 4, filing 0000919574-19-003830 | |
| 2019-05-21 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 9,995 acquired | 8.52 | 85,108.42 | Form 4, filing 0000919574-19-003830 | |
| 2019-05-20 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 8,285 acquired | 7.98 | 66,141.64 | Form 4, filing 0000919574-19-003792 | |
| 2019-05-20 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 1,715 acquired | 8.39 | 14,383.19 | Form 4, filing 0000919574-19-003792 | |
| 2019-05-17 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 6,200 acquired | 7.36 | 45,641.30 | Form 4, filing 0000919574-19-003792 | |
| 2019-05-16 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 5,408 acquired | 6.79 | 36,718.16 | Form 4, filing 0000919574-19-003792 | |
| 2019-03-18 |
Axovant Sciences Ltd. AXON |
P, Open-market purchase | 6,666,667 acquired | 1.50 | 10,000,000.50 | Form 4, filing 0001104659-19-016034 | |
| 2018-12-18 |
Axovant Sciences Ltd. AXON |
P, Open-market purchase | 10,000,000 acquired | 1.00 | 10,000,000.00 | Form 4, filing 0001104659-18-073942 | |
| 2018-10-01 |
Urovant Sciences Ltd. UROV |
P, Open-market purchase | 2,678,571 acquired | 14.00 | 37,499,994.00 | Form 4, filing 0001104659-18-060388 | |
| 2018-06-05 |
Axovant Sciences Ltd. AXON |
P, Open-market purchase | 14,285,714 acquired | 1.75 | 24,999,999.50 | Form 4, filing 0001104659-18-038782 | |
| 2018-04-02 |
Myovant Sciences Ltd. MYOV |
P, Open-market purchase | 1,110,015 acquired | 20.27 | 22,500,004.05 | Form 4, filing 0001104659-18-022441 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 35
- Open-market sale 5
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Lo Andrew, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001679076
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6